Clinical trial
Flavopiridol in Treating Patients With Refractory Cancer
NCT00019344 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019344 |
|---|---|
| Title | Flavopiridol in Treating Patients With Refractory Cancer |
| Official title | A Phase I Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Refractory Neoplasms |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | alvocidib |
| Start date | Aug 1, 1997 |
| First posted | Apr 21, 2004 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: